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ABSTRACT 
 
The brain is one of the most important organs in the body. It functions as a 
control center by regulating and coordinating actions and reactions, which is 
facilitated via signal transduction pathways. Its function is primarily dependent 
upon sufficient supply of glucose for energy metabolism. The dysfunction of the 
brain resulting from an external force is known as traumatic brain injury (TBI). 
Symptoms range from physical to psychological and effects can be mild, 
moderate, or severe depending on the extent of injury. TBI is associated with 
oxidative damage the overproduction of reactive oxygen/nitrogen species. 
Reduced energy metabolism is a consequence of traumatic brain injury, while 
reduced purine salvage is associated with deficient cell signaling. Previous 
studies have demonstrated that the administration of gamma-glutamylcysteine 
ethyl ester (GCEE) following TBI has protective effects against protein nitration. 
This study investigates the enzymatic activity of energy related and salvage 
related enzymes, glyceraldehyde-3-phosphate dehydrogenase, pyruvate kinase, 
lactate dehydrogenase, aspartate aminotransferase, malate dehydrogenase, 
cytochrome C oxidase, ATP synthase, and hypoxanthine-guanine 
phosphoribosyltransferase, that have been identified as excessively nitrated 
following the administration of GCEE post-TBI. Adult male Wistar rats were 
divided equally into three groups: sham, saline, and GCEE. Rats in all groups 
(except sham) were subjected to a craniotomy and a moderate TBI via cortical 
contusion. Post-TBI rats in the saline group received an administration of saline 
vii 
 
(150mg/kg), and rats in the GCEE treatment group received an administration of 
GCEE (same dosage). Upon sacrifice, brains were harvested and enzymatic 
activity was indirectly measured spectrophotometrically. Data demonstrates that 
the administration of GCEE following brain trauma increases enzymatic activity. 
Our results are promising and indicate potential therapeutic strategies to restore 
energy and salvage related enzymatic activity in the brain post-TBI. 
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CHAPTER 1 
INTRODUCTION 
 
Traumatic brain injury (TBI) is a sudden event that results in the disruption 
of proper brain functionality and is caused by an external force, such as a blow to 
the head. Symptoms range from physical to psychological while effects can be 
mild, moderate, or severe depending on the extent of the injury experienced. 
Many people who experience TBI face progressive, lifelong physical disabilities 
and cognitive impairments. In the past, injury from head trauma was considered 
instantaneous and irreversible. Now it is clear that there are two phases of injury: 
primary and secondary. Upon insult of injury, the primary physical damage 
sustained by the brain alters biochemical and cellular pathways.  Secondary 
injury then begins as a byproduct of the biochemical and cellular disruptions of 
primary injury, and is a progressive cytotoxic cascade causing damage 
accumulation, TBI progression, and neurodegeneration, over an extended period 
of time.  
Membrane depolarization, a direct consequence of primary injury, initiates 
the progressive cytotoxic cascade of damage-accumulating events by causing 
the uncontrolled release of glutamate in the synaptic gap. The excessive 
amounts of glutamate cause the hyper-activation of glutamate receptors, which 
consequently cause a mass influx of calcium into the neuronal cells. As a result 
of this glutamate-induced excitotoxicity and calcium overload, reactive oxygen 
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(ROS) and reactive nitrogen species (RNS) are overproduced. Typically, the 
production of ROS is an aftereffect of oxygen metabolism; however, a host of 
studies investigating the molecular and cellular pathophysiological consequences 
of traumatic brain injury have found correlated associations with oxidative 
damage and protein nitration. Oxidative stress is characterized as an imbalance 
between free radicals and antioxidants that result from the body’s inability to 
counteract the enhanced formation of ROS/RNS. The suppression of enhanced 
reactive oxygen species formation, in part, decreases the production of reactive 
nitrogen species, as RNS are derived from ROS interactions with nitric oxide, 
peroxynitrite, and peroxynitrite derivatives. Some proteins have an increased 
susceptibility to oxidative damage and undergo nitration, which results in 
structural and function loss. The culmination of effects from oxidative damage 
and protein nitration seen in persons with TBI leads to diminished antioxidant 
capacities and increased tissue loss (Shao et al. 2006). 
Despite the various elucidations of TBI pathological consequences, no 
known federally approved therapeutic agent is available to disrupt its secondary 
injury processes. However, several studies demonstrate that therapeutic 
approaches utilizing antioxidants effectively prevent neurodegeneration by 
protecting neurons against oxidative stress. Innately, cells utilize a host of 
mechanisms for protection from ROS. These mechanisms include the 
implementations of superoxide dismutase, catalase, and antioxidants. Most 
notably, antioxidants, such as glutathione, inhibit oxidation by scavenging 
ROS/RNS. In circumstances of ROS/RNS overproduction, these neuroprotective 
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mechanisms are exhausted due to limited availability of substrates. Recent 
studies have investigated the administration of chemical substances that boost 
intracellular glutathione, as the administration of glutathione itself is ineffective. 
Gamma-glutamylcysteine ethyl ester (GCEE) is an ethyl ester moiety of gamma-
glutamylcysteine, which is a glutathione precursor compound that exhibits 
antioxidant activity by increasing glutathione production (Reed et al. 2009). 
Previous studies demonstrated that the administration of GCEE following TBI has 
protective effects against protein nitration (Reed et al. 2009, Lok et al. 2011). 
Mass spectral analysis previously performed by our collaborator, Dr. 
Sowell, indicates that energy-related and purine salvage enzymes are nitrated, 
thereby resulting in reduced energy metabolism and nucleotide salvage. Thus, 
the purpose of this study was to conduct a series of investigations that assessed 
the efficacy of GCEE as a neuroprotective therapeutic strategy for TBI by 
determining the optimum time point for treatment. The first study (Chapter 4) was 
conducted to assess the activity of energy related proteins post-TBI and 
determine if the administration of GCEE post-injury normalized enzymatic activity 
in experimental TBI brain through its ability to elevate intracellular glutathione 
levels and attenuate oxidative stress. The second study (Chapter 5) assessed 
and determined the activity of purine salvage enzyme hypoxanthine-guanine 
phosphoribosyltransferase with respect to GCEE administrative effects post-TBI.  
. 
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CHAPTER 2 
BACKGROUND 
 
2.1 Traumatic Brain Injury 
2.1.1 Overview 
Traumatic brain injury is a serious medical issue and public health concern 
of significant proportions, as it is a leading cause of death and long-term disability 
in disproportionately affected heterogeneous populations worldwide, with an 
increasing burden of indirect and direct expenses associated with a lack of 
successful therapeutic strategies (Hyder et al. 2007, Bruns and Hauser 2003, 
Kabadi and Faden 2014). Higher incidences of traumatic brain injury are reported 
in individuals of minority descent and low socioeconomic status (Bruns and 
Hauser 2003). Studies confirm that this incidence and prevalence is increased in 
early childhood, late adolescence/early adulthood, and elderly populations (Bruns 
and Hauser 2003). The high incidence in these groups may be attributed to a 
culmination of factors, such as recreational sports, motor vehicle accidents, 
reduced motor skills, and physical abuse, according to the National Center for 
Injury Prevention and Control at the Centers for Disease Control (CDC). A 
collection of studies demonstrate the association of gender differences and TBI 
(Bazarian et al. 2010, Farace and Alves 2000, Ottochian et al. 2009). Females 
experience higher mortality and fatality rates from traumatic brain injury (Farace 
and Alves 2000, Ottochian et al. 2009). Ultimately, evidence suggests that TBI 
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can affect virtually everyone, considering risk factors and increasing incidence 
and prevalence rates. 
2.1.2 Classification 
Traumatic brain injury can be classified in numerous ways. These 
classifications are determined by characterizations of severity, type, skull 
exposure, damage, and injury. Clinically, the use of the Glasgow Coma Scale 
(GCS) is the instrument utilized to assess and classify the severity of TBI. 
Severity of brain injury can be categorized as mild, moderate, or severe (Table 
1). The GCS is comprised of three parameters which evaluate one’s responses 
of eye opening, verbal function, and motor function to various stimuli (Teasdale 
and Jennett 1974). Scores range from 3 to 15, where a score of 3 is considered 
the most severe (diminished capacity) and a score of 15 is considered least 
severe (normal ability). Persons receiving a total score of 13 to 15 is considered 
to have experienced a mild injury, scores of 9 to 12 are indicative of a moderate 
injury, and scores of 3 to 8 are indicative of severe TBI.  
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Table 2.1 Glasgow Coma Scale 
Response Mechanism Scale Score 
 
Eye Opening 
Spontaneously 4 
To speech 3 
To pain only 2 
No response 1 
 
Verbal Function 
Oriented 5 
Confused 4 
Inappropriate words 3 
Incomprehensible sounds 2 
No response 1 
 
Motor Function 
Obeys commands 6 
Localizes to pain 5 
Withdraws from pain 4 
Abnormal flexion 3 
 
Severity classification is contingent upon TBI type. The five types of 
traumatic brain injury are concussion, contusion, coup-contrecoup injury, diffuse 
axonal injury, and penetration (Chung and Khan 2013). The mildest and most 
common type of TBI experienced is a concussion. Although it is possible for 
anyone to sustain a concussion, recreational and professional athletes have an 
inherent risk, as participation in most sporting events involves high velocity 
collisional contact (Covassin, Stearne, and Elbin 2008, McKee 2014). Individuals 
with a concussion experience a host of medical manifestations, including 
headache, confusion, dizziness, blurred vision, tinnitus, hyposmia, hyperacusis, 
fatigue, and brief loss of consciousness. These are collectively referred to as 
post-concussive somatic symptoms (McAllister and Arciniegas 2002). These 
somatic symptoms along with cognitive and behavioral changes experienced 
post-concussion are commonly referred to as post-concussion syndrome (PCS), 
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and typically have a brief duration that resolves within weeks (Daneshvar et al. 
2011). However, in persons who experience concussions more “routinely”, such 
as athletes, the deficits PCS presents can linger for months or longer. The 
persistence of PCS along with frequent and repeated incidences of concussions 
increase susceptibility of a person developing a more severe TBI.  
Contusions and coup-contrecoup injury are moderate forms of TBI that 
exert post-concussive somatic symptoms with increased loss of consciousness. 
A contusion is characterized as bleeding on the brain that occurs at the site of 
impact, whereas in coup-contrecoup injury bleeding is experienced both at and 
away from the site of impact. Severe forms of traumatic brain injury include 
diffuse axonal injury and penetration. Tearing of brain structures occurs in diffuse 
axonal injury, when an object directly breaches through the skull into the brain in 
penetration. Persons who experience these severe types of TBI exhibit post-
concussive symptoms with extreme loss of consciousness or coma. 
Head trauma is classified by skull exposure, which can be referred to as 
an open or closed head trauma. This classification is contingent upon the lancing 
of the dura mater, one of the three protective layers of the brain. If a head injury 
pierces the dura mater, it is considered open; and if it does not it, is classified as 
a closed injury. Concussions, contusions, coup-contrecoup injuries, and diffuse 
axonal injuries are considered closed head injuries, whereas penetration is 
defined as an open head injury. Closed head trauma has inversely proportional 
prevalence, mortality, and fatality rates compared to open head trauma, as open 
head injury has a lower prevalence  but higher mortality and fatality rates (Kazim 
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et al. 2011). Head injury is further categorized by damage distribution. The 
distribution of damage in terms of location is referred to as focal or diffuse. If TBI 
is focal, damage occurs at the site of impact, with damage localized to those 
areas. Alternatively, if TBI is diffuse, damage occurs over a more widespread 
area without solid structure impact. Open head trauma tends to be largely focal, 
while persons who experience closed head trauma experience focal and diffuse 
damage. 
Previously, injury from head trauma was considered to be instantaneous 
and irreversible. Recent research shows that there are two phases of injury: 
primary and secondary (Werner and Engelhard 2007). Primary injury occurs at 
the instant the trauma occurs, and represents the immediate resultant physical 
damage. Secondary injury begins as a product of disruption from primary injury 
and is a progressive cytotoxic cascade causing damage accumulation, and TBI 
progression, over an extended period of time. Given that TBI is known to be an 
accumulative process, there is potential for improving therapeutic intervention. 
2.1.3 Treatment 
Currently, there are no FDA approved pharmaceutical interventions to 
interrupt or inhibit damage from secondary TBI, despite the attempts of 
preclinical studies to assess the efficacy of drugs for neuroprotection (Xiong, 
Mahmood, and Chopp 2009). Similarly, approaches to various treatments tested 
in clinical trials have all failed to show efficacy with the exception of induced 
hypothermia, as they target single factors (Doppenberg, Choi, and Bullock 2004, 
Peterson, Carson, and Carney 2008). Targeted temperature management via 
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induction of hypothermia is an approved non-pharmacological approach to TBI, 
as it promotes neuronal integrity by inhibiting ischemia inhibition. However, 
hypothermia as a treatment for TBI has been recommended for optional and 
cautious use, as its benefits are offset by an increased risk of developing 
pneumonia (Xiong, Mahmood, and Chopp 2009, Peterson, Carson, and Carney 
2008). Given the complexity of primary and secondary injury mechanisms that 
exist in traumatic brain injury, neuroprotective strategies should reflect the 
cascade of interactive factors that contribute to damage accumulation. Current 
research demonstrates therapeutic promise as potential treatments strategically 
and simultaneously address the multiple potential effects of injury factors. 
Recent investigations of the pleiotropic properties of statins and 
cyclosporin A as neuroprotective agents for TBI have resulted in significant 
improvement of outcomes after injury. Statins, a class of drugs that ultimately 
inhibit the biosynthesis of cholesterol, are typically prescribed to patients in an 
effort to prevent heart disease. However, the use of statins demonstrate 
beneficial effects unrelated to cholesterol in brain injury models, such as anti-
inflammatory, antioxidant, anti-excitotoxic, anti-apoptotic, and neurogenic 
properties (Wible and Laskowitz 2010). These effects, respective to the wide 
therapeutic window for treatment (24 hours), are influential in targeting the 
multiple mechanisms of secondary injury by limiting production and expression of 
inflammatory mediators, decreasing lipid peroxidation, increasing neuronal 
survival, and improving cognitive function (Loane and Faden 2010). Similarly to 
statins, cyclosporin A exhibits neuroprotective effects in TBI models, although it 
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is FDA-approved for other clinical purposes and has a large therapeutic window. 
This immunosuppressant drug attenuates oxidative stress, lipid peroxidation, and 
mitochondrial failure often experienced in post-traumatic brain injury by 
stabilizing the mitochondrial permeability transition pore (Kabadi and Faden 
2014, Okonkwo and Povlishock 1999).  
 
2.2 Reactive Oxygen and Nitrogen Species 
2.2.1 Overview 
 Reactive oxygen and nitrogen species (ROS/RNS), classified as either 
free radicals or as non-radicals, are generated in small amounts by cellular redox 
processes, such as the reduction of oxygen in the mitochondria to produce 
adenosine triphosphate (ATP) (Trachootham et al. 2008). When produced in 
excess ROS/RNS impair cellular homeostasis. Exogenous and endogenous 
defense mechanisms exist to combat, decrease, and eliminate excess 
ROS/RNS. Examples of these defense mechanisms that restore redox balance 
include the cellular antioxidant glutathione as well as a number of enzymes, such 
as superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx) 
(Apostolova and Victor 2015). 
2.2.2 Free Radicals 
Free radicals are species that possess at least one unpaired electron, 
whereas non-radicals, such as hydrogen peroxide and peroxynitrite, lack 
unpaired electron(s) (Vladimirov 1998). Aside from electron possession, radicals 
are characterized by their stability, in terms of reactivity and persistence 
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(Karogodina, Sergeeva, and Stass 2011). Radical stability and reactivity refers to 
internal energy level. The higher the energy level, the more unstable the radical 
is. Unstable radicals are considered highly reactive because they will attempt to 
reach a lower energy level. Hence, free radicals are considered extremely 
reactive as they have a great propensity to achieve stability via electron(s) 
donation and extraction, while non-radicals are not as reactive as they are more 
stable (Halliwell 2006). Persistence of a radical refers to their length of life. Non-
radicals are said to have a longer life or persistence than that of a free radical, 
because of its stability and low reactivity. Despite differences in persistence, 
radicals are generally and collectively short lived. 
2.2.3 Oxygen 
In terms of ROS, oxygen (O2) is increasingly susceptible to radical 
formation, as its lacks paired electrons. The consecutive reduction of oxygen via 
electron donation generates a number of ROS, which include, superoxide (•O2), 
hydrogen peroxide (H2O2), and hydroxyl radical (•OH).  Diatomic oxygen is also 
responsible for the formation of RNS, as peroxynitrite (PN: ONOO-) is produced 
by the reaction of nitric oxide (•ON), a reactive nitrogen species (RNS), and •O2. 
Thus, it can be said that O2 is important in the derivation of ROS/RNS. 
 
O2
e-
→O2
- e
-+ 2H
+
→    H2O2
e-+ H
+ 
→    OH• 
Fig. 2.1 Formation of hydroxyl radical through electron transfer 
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2.2.4 Superoxide, Hydrogen Peroxide, and Hydroxyl Radical 
 As illustrated in Figure 2.1, superoxide is produced by the reduction of one 
molecule of oxygen with an electron. This transfer of an electron to O2 is 
conducted by cytochromes within the mitochondria. Given the high reactivity of 
•O2, the enzyme superoxide dismutase (SOD) acts as a catalyst to rapidly 
facilitate the neutralization of •O2. This neutralization of reactivity involves the 
reduction of •O2 to H2O2. Superoxide dismutase is a protein that is commonly 
oxidatively modified in neurodegenerative disorders such as Alzheimer’s disease 
and Parkinson’s disease (Choi et al. 2005).  
In excess accumulation, superoxide and hydrogen peroxide have the 
capacity to induce profound effects on mitochondrial function via production of 
other ROS (Hall, Vaishnav, and Mustafa 2010). Thus the elimination of H2O2 by 
catalase and glutathione proves pivotal in reducing the damaging effects of ROS 
(Baud et al. 2004). Catalase and glutathione peroxidase are responsible for the 
decomposition of H2O2 into water (H2O) and O2. Hydroxyl radicals are considered 
the most toxic ROS, because their ability to react with any molecule to balance 
their unpaired electrons is limitless. Secondly, their inability to be eliminated 
through enzymatic means, unlike •O2 and H2O2, contribute to their increased 
toxicity. Hydroxyl radicals are generated from H2O2 in the presence of high 
“catalytic acting” metals. Reactions such as the Fenton reaction demonstrate the 
cyclic production of •OH from H2O2 with the aid of metals.  
In the Fenton reaction (Fig.2.2), ferrous iron (Fe2+) is oxidized into ferric  
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iron (Fe3+), and then reduced by superoxide (Haber and Weiss 1934). The 
reduction results in the production of ferrous iron, which can be cycled into 
another Fenton reaction (Haber and Weiss 1934). High concentrations of iron 
result in an acceleration of radical reactions. Iron-containing proteins, such as 
transferrin and hemoglobin, have an overwhelming presence and high affinity for 
iron at physiological pH (Halliwell and Gutteridge 1988). Hence, free ionic iron is 
almost nonexistent. At conditions in which pH is lowered, the affinity for iron is 
reduced within iron storing proteins (Halliwell and Gutteridge 1986). Therefore 
this reduction results in the mobilization of iron, which in turn increases the 
production of •OH (Halliwell and Gutteridge 1986).  
 
 H2O2 +  Fe
2+
→ •OH + OH
-
 + Fe3+ 
Fig.2.2 Fenton Reaction 
 
2.2.5 Nitric Oxide and Peroxynitrite 
  Though moderately toxic, nitric oxide is involved in many cellular 
activities within the body.  Uniquely, high concentrations of •ON allow it to 
surpass superoxide dismutase in competition for •O2 (Beckman and Koppenol 
1996). The coupling of •ON and •O2 produce peroxynititrite. Peroxynitrite is 
considered a selective oxidant as its reactivity with biological molecules is 
gradual, because it lacks an unpaired electron (Beckman and Koppenol 1996). 
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Despite the limited reactivity of PN, its derivatives, such as nitrite radical (•NO2) 
and carbonate radical (•CO3), are extremely reactive and very toxic. 
 
2.3 Molecular and Cellular Consequences of Traumatic Brain Injury 
2.3.1 Overview 
  Aside from primary (mechanical) damage, TBI induces a host of 
secondary insults that collectively contribute to oxidative damage. Excitotoxicity, 
calcium (Ca2+) overload, and reactive oxygen species are the primary 
participants in mitochondria-centered cell damage. The culmination of these 
sequential contributors ultimately result in lipid peroxidation and protein nitration, 
both oxidative protein modifications. Oxidative damage experienced post-
traumatic brain injury is irreversible and influential in neurodegeneration. 
2.3.2 Glutamate-induced Excitotoxicity 
 A neurotransmitter is defined as a chemical messenger that facilitates 
the transmission of signals between neurons, and can be classified as excitatory 
or inhibitory. Excitatory neurotransmitters “excite” or stimulate other neurons 
resulting in firing of action potentials, while inhibitory neurotransmitters prevent 
the generation of action potentials. Among the host of excitatory 
neurotransmitters found in the brain, glutamate is the most abundant. Typically 
low concentrations of glutamate are found in the extracellular space. However, 
membrane depolarization, a consequence of primary traumatic brain injury, 
increases the concentration of glutamate post-TBI due to the lack of inhibition 
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regarding glutamate release (Yi and Hazell 2006, Choi 1994, Hartings et al. 
2009).   
 Glutamate excitotoxicity refers to the excessive activation of glutamate 
receptors, N-methyl-D-aspartate (NMDA), a-amino-3-hydroxyl-5-methyl-4-
isoxazolepropionate (AMPA) and kainite (Mark et al. 2001). These receptors are 
collectively responsible for the activation of ion channels that promote the influx 
of Ca2+ (Mark et al. 2001). The binding of extreme levels of glutamate to these 
receptors result in an enormous influx of Ca2+ into neurons, which 
consequentially leads to the overproduction of ROS/RNS, excitotoxicity, and 
possibly death (Weber 2012). 
2.3.3 Overproduction of Reactive Oxygen Species 
  Mitochondrial uptake of Ca2+ results in the stimulation of ROS 
overproduction via mitochondrial permeability transition pore (MPT) activation 
(Cheng 2012, Starkov, Cinopoulous, and Fiskum 2004). This activation results in 
the release of cytochrome c and loss of intra-mitochondrial glutathione (Starkov, 
Cinopoulous, and Fiskum 2004). The release of cytochrome C results in 
stimulated •O2 production (Cai, Yang, and Jones 1998). The consequential loss 
of intra-mitochondrial glutathione upon MPT activation results in the inability to 
detoxify H2O2 and stop the ongoing cascade of ROS production. Although there 
are numerous mitochondrial sources that contribute to the overproduction of 
ROS, it is important to consider aftereffects of MPT activation, as the electron 
transport chain is the primary location of hydroxyl radical production post-TBI. 
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2.3.4 Lipid Peroxidation  
 The brain, being largely composed of polyunsaturated fatty acids, is 
extremely susceptible to lipid peroxidation (LP), as the overproduction of ROS 
occurs post-TBI (Lok et al. 2011). Lipid peroxidation is defined as the oxidation of 
lipids via ROS, and can be divided into three stages: initiation, propagation, and 
termination (Fig.2.3). The chain reaction of LP is initiated by the formation of a 
lipid radical (•L) via •OH extraction of a hydrogen atom. During lipid peroxidation 
propagation, •L readily reacts with •O2 to form a lipid peroxyl radical (•LOO). The 
instability and high reactivity of •LOO with lipid hydroperoxide formation 
perpetuates the production of other lipid peroxyl radical, until termination.  
Termination occurs once lipid availability depletes or stability is achieved via non-
radical species production and/or antioxidant detoxification. 
 
Fig.2.3 Illustration of lipid peroxidation 
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2.3.5 Protein Nitration 
The nitration of proteins leads to a wide variety of structural and functional 
consequences, and is induced by the introduction of oxygen and nitrogen 
compounds, such as the LP derivatives •CO3 and •NO2. ROS/RNS specifically 
target amino acids that contain hydroxyl or amine groups, such as tyrosine and 
proline (Corpas et al. 2009). Thus it can be said the level of protein susceptibility 
to oxidative and nitrosative damage is contingent upon functional group 
possession. In all common forms of TBI, protein dysfunction has been 
demonstrated as a consequence of protein nitration (Deng et al. 2007, Orihara et 
al. 2001). 
 
2.4 Glutathione 
2.4.1 Overview 
The ubiquitous tripeptide glutathione, composed of glutamate (Glu), 
cysteine (Cys), and glycine (Gly), is an important component of antioxidant 
defense, as it behaves as both a substrate for glutathione peroxidase in the 
removal of H2O2, and as a free radical scavenger (Winterbourn and Metodiewa 
1994). The ability of glutathione to act as an antioxidant is primarily governed by 
its active thiol group, which is in the form of a cysteine residue. The antioxidant 
stability of glutathione is enhanced by the atypical γ-peptide linkage between Glu 
and Cys, which protects glutathione from hydrolysis (Wu et al. 2004). Glutathione 
exists in reduced and oxidized forms, GSH and GSSG, respectively. The 
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recycling of glutathione, interconversion of GSH to GSSG, is critical for 
maintaining redox balance. 
2.4.2 Biosynthesis 
 Glutathione biosynthesis consists of two sequential ATP-dependent 
reactions catalyzed by gamma-glutamylcysteine synthetase (GCS) and 
glutathione synthetase (GS), and is tightly regulated by GCS, cysteine 
availability, and GSH feedback inhibition (Noctor et al. 1997). The initial reaction 
consists of the formation of gamma-glutamylcysteine (γ-GluCys) via γ-peptide 
linkage between Glu and Cys. Glutathione is then produced via catalysis of γ-
GluCys coupling to Gly.   
2.4.3 Metabolism 
Glutathione is critical in terms of cellular defense against ROS, as it 
functions as an antioxidant. Glutathione effectively participates as a ROS/RNS 
scavenger directly by detoxification and indirectly through enzymatic reactions. In 
such reactions, •OH, •ON, and ONOO- are removed directly via reduction with 
GSH, while enzymatic catalysis by glutathione peroxidase removes H2O2. Both 
reactions lead to the generation of oxidized glutathione, which is recycled via 
reduction to form GSH using NADPH and glutathione reductase (Dringen 2000) 
(Fig.2.4). 
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Fig.2.4 Illustration of glutathione recycling 
 
2.4.4 Upregulation of Glutathione 
 The role of glutathione in maintaining redox equilibrium is immense, as the 
loss and eventual depletion of glutathione decreases the reducing capacity of the 
cell and increases the levels of ROS/RNS (Martin and Teismann 2009). The high 
levels of ROS/RNS associated with glutathione depletion causes oxidative 
stress-mediated neuronal dysfunction and death. To ameliorate the deleterious 
effects of glutathione depletion and oxidative stress, glutathione levels must be 
elevated. 
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Strategies to increase glutathione levels have been investigated, as the 
administration of crude glutathione has been deemed ineffective (Lash and 
Jones 1985, Ammon, Melien, and Verspohl 1986, Wendel and Jaeschke 1982). 
Much of the research investigating the upregulation of glutathione biosynthesis 
has been aimed at providing cysteine to the cell, as this is the limiting amino acid 
in glutathione biosynthesis and exists in the brain at lower concentrations than 
Glu and Gly (Drake et al. 2002). Among the glutathione precursors that have 
been demonstrated to increase cellular glutathione levels, gamma-
glutamylcysteine (GCEE) uniquely circumvents the feedback inhibition (Drake et 
al. 2002). GCEE, an analog compound of γ-glutamylcysteine with an ethyl ester 
moiety addition, has been demonstrated to have neuroprotective effects against 
protein nitration and oxidative stress through glutathione elevation (Reed et al. 
2009, Drake et al. 2002, Lok et al. 2011).   
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CHAPTER 3 
 EXPERIMENTAL METHODS 
 
3.1 Controlled Cortical Impact 
 TBI is a disease of great complexity, as there is no known drug to interrupt 
and inhibit its pathological consequences. However, the utilization of animal 
models in TBI research aids in the identification and assessment of potential 
neuroprotective therapeutics. Given the varying heterogeneities of TBI, such as 
physical, behavioral, and histopathological changes, the use of animal models 
are preferred as researchers are able to investigate single factors in the 
pathobiology through experimental design. Whereas the constraints of 
experimental control in human subjects TBI research is limited as the injury type, 
severity, and condition change dynamically.  
In lieu of the heterogeneous nature of TBI, experimental designs to induce 
TBI vary, and include fluid percussion injury model, controlled cortical impact 
(CCI) injury model, penetrating ballistic-like injury model, weight drop model, and 
blast model, (Xiong, Mahmood, and Chopp 2013). The selection of an injury 
model to implement in experimental design is based upon its varying strengths 
and weaknesses in regards to the research question. In this study, CCI was 
selected as the injury model of use for a number of reasons. Our primary reason 
for this choice was the ease in manipulating mechanical factors, such as time, 
velocity, and impact depth, allowing for the selection of injury severity induced. 
CCI also can focally localize injury, decreasing the risk of rebound injury.  
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Upon approval of animal surgical procedures by the University of Kentucky 
Institutional Animal Care and Use Committee, animals were housed in the 
Division of Laboratory Animal Resources at the University of Kentucky in a 12 
hour light/dark cycle with ad libitum access to feed. Eighteen adult male Wistar 
rats (Harlan Laboratories, Indianapolis, IN, USA) were equally divided into three 
experimental groups: sham, saline, and GCEE. Animals were shaved to remove 
hair on the scalp and anesthetized using isoflurane (3.0%) prior to being placed 
in a stereotaxic frame (David Kopf Instruments, Tujunga, CA) for surgery. 
Surgery was completed and conducted in the same fashion as previously 
described by Sullivan (Sullivan et al. 2002). Upon placement in the frame, rats 
underwent a craniotomy, a surgical process that allows access to the brain via 
skull cap removal. A metal ball was dropped from the impactor on the cortex of 
the exposed brains of the vehicle and treatment groups, saline and GCEE 
respectively, at a 1.5 mm depth to simulate a moderate TBI, in the form of 
contusion. A 4 mm disk made from dental cement was placed over the site of the 
surgery and/or injury and adhered to the skull with cyanoacrylate. The skull cap 
was then returned and the skin was sutured. Rats were placed on a heating pad 
until consciousness and mobility were regained.  
3.2 Spectrophotometric Enzyme Assays 
 Proteins have a host of functions within cells. Proteins termed enzymes 
are biological catalysts that work by lowering activation energy.  A large number 
of studies indicate that posttranslational modifications of proteins, such as 
nitration and oxidation, alter protein function. Reductions in energy metabolism 
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and protein catabolism have been reported post-TBI (Weinzierl et al. 2002, Yao, 
Liu, and McCabe 2007). In an effort to assess the activity of energy related and 
purine salvage enzymes post-TBI, various spectrophotometric enzyme assays 
were conducted in this research study.  
The use of spectrophotometric assays allowed the detection of changes in 
substrate absorbance values. This change was measured by the appearance of 
product or the disappearance of substrate. In circumstances in which substrates 
or products were incapable of absorbing light at wavelengths detectable by the 
spectrophotometer, reactions were coupled. In coupling reactions, the product of 
one reaction is used as a substrate for another reaction. 
 All reagents utilized in the assay reaction mixtures were prepared in 
deionized water or buffer specific to the enzyme of interest. Appropriate volumes 
of reaction reagents and enzymes were added to each respective microplate to 
reach a final volume of 200 µL per well. Microplate wells serving as negative 
controls (“blank”) lack test samples and enzyme, and have an increased volume 
of buffer in comparison to wells housing enzyme and samples. Wells containing 
the enzyme of interest or samples are respectively referred to as positive controls 
and analytes. The addition of equivalent volumes of enzyme or samples in wells 
respective to their designation initiates the reactions. Upon initiation, the 
reactions were incubated and monitored at specific wavelengths and 
temperatures for 15 minutes using a plate reader. All reactions in each assay are 
performed in triplicate and incubated at room temperature unless noted 
otherwise. 
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3.2.1 Glyceraldehyde-3-phosphate dehydrogenase 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is the 
oxidoreductase responsible for many processes in glycolysis, such as producing 
ATP through substrate level phosphorylation and reducing NAD+ to NADH. Apart 
from its role in glucose metabolism, GAPDH acts as an intracellular sensor of 
oxidative stress in the initiation of apoptosis, and is involved in membrane 
trafficking and nuclear translocation (Chuang, Hough, and Senatorov 2005, 
Ventura et al. 2010, Tristan et al. 2011). Given its wide array of participation in 
cellular events, aberrant activity is suggestive of pathological consequences, 
such as abnormal cell proliferation and carcinogenesis. Thus the quantitation of 
glyceraldehyde-3-phosphate dehydrogenase provides insight into normal cellular 
physiology and the detection of disease. 
The GAPDH assay is a coupled spectrophotometric assay used in 
indirectly measuring the activity of GAPDH via determination of the number of 
moles of glycerate-1,3 bisphosphate converted to glyceraldehyde-3-phosphate at 
340 nm (Fig.3.1). In this assay, the substrate, glycerate-1,3 bisphosphate is 
produced by the ATP-dependent phosphorylation of 3-phosphoglyceric acid (3-
PGA) catalyzed by 3-phosphoglyceric phosphokinase (3-PGK) (Fig.3.1, step 1). 
Then glycerate-1,3 bisphosphate is reduced by β-nicotinamide adenine 
dinucleotide (β-NADH) to glyceraldehyde-3-phosphate (G-3-P) and inorganic 
phosphate in the presence of glyceraldehyde-3-phosphate dehydrogenase 
(Fig.3.1, step 2).  
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Fig.3.1 Enzymatic reaction of glyceraldehyde-3-phosphate dehydrogenase assay 
  
All reagents were prepared using deionized water, with the exception of 
the GAPDH enzyme solution, which was prepared using 100 mM triethanolamine 
buffer (pH 7.6). Reaction reagents, as found in Table 3.1, were added to the 
microplate and mixed prior to insertion into the plate reader. 
 
Table 3.1 Glyceraldehyde-3-phosphate dehydrogenase assay reagents 
 (volume per well) 
 
Reagent Blank Positive 
Control 
100 mM Triethanolamine hydrochloride 166.8 µL 160 µL 
100 mM D(-) 3-phosphoglyceric acid 13.3 µL 13.3 µL 
200 mM L-cysteine hydrochloride 3.3 µL 3.3 µL 
7 mM β-NADH 3.3 µL 3.3 µL 
100 mM MgSO4 3.3 µL 3.3 µL 
34 mM ATP 6.7 µL 6.7 µL 
200 U/mL 3-phosphoglyceric 
phosphokinase 
3.3 µL 3.3 µL 
0.6 U/mL GAPDH enzyme solution  - 6.8 µL 
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3.2.2 Pyruvate kinase  
 Pyruvate kinase (PK) is an essential enzyme in glucose metabolism as it 
catalyzes the conversion of phosphoenolpyruvate (PEP) into pyruvate, and 
assists in the production of ATP via phosphoryl group transfer from PEP to 
adenosine diphosphate (ADP), in the final irreversible step of glycolysis (Fig.3.2). 
Pyruvate produced from this reaction serves as an intermediate in connecting 
glycolysis and the TCA cycle. Thus the strict regulation of PK activity is of 
immense importance in overall cellular metabolism. The pyruvate kinase assay, a 
coupled enzyme assay, is often implemented to assess the enzymatic activity of 
PK, as defects in activity impede glycolysis, while the absence of PK is causal to 
the development of hemolytic anemia. This two-step reaction assay is monitored 
at 340 nm upon initiation, and results in the generation of pyruvate and ATP 
(Fig.3.2, step 1). Pyruvate produced in the initial reaction is used as a substrate 
to produce lactate in the second reaction via coupling with β-NADH in the 
presence of lactic dehydrogenase (LDH) (Fig.3.2, step 2).  
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Fig.3.2 Enzymatic reaction of pyruvate kinase assay 
 
All reagents found in Table 3.2 were prepared using deionized water, with 
the exception of L-lactic dehydrogenase and pyruvate kinase enzyme solutions, 
which were prepared using 100 mM KH2PO4 buffer (pH 7.6 at 37°C). The 
reaction mixture was mixed and equilibrated to 37°C. Pyruvate kinase enzyme 
solution or sample was then added to initiate the reaction. 
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Table 3.2 Pyruvate kinase assay reagents (volume per well) 
Reagent Blank Positive Control 
dH2O 93.3 µL 93.3 µL 
100 mM KH2PO4 53.3 µL 60 µL 
8 mM PEP 10.7 µL 10.7 µL 
3 mM β-NADH 13.3 µL 13.3 µL 
100 mM MgSO4 13.3 µL 13.3 µL 
40 mM ADP 6.7 µL 6.7 µL 
500 U/mL LDH 2.7 µL 2.7 µL 
0.6 U/mL PK  - 6.7 µL 
 
3.2.3 Lactate dehydrogenase  
Lactate dehydrogenase (LDH), an oxidoreductase responsible for the 
reduction of pyruvate to lactate (Fig 3.3), is present in a wide variety of tissues 
within the body. LDH levels are elevated and released into the bloodstream upon 
injury, disease, or exposure to toxic material. Thus, clinical quantification of this 
enzyme is used to investigate pathological conditions and assess tissue damage 
and toxicity.  
 
 
Fig 3.3 Enzymatic reaction of lactate dehydrogenase 
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In assaying the activity of LDH post-TBI, all reaction reagents were 
prepared using 100 Mm NaH2PO4 (pH 7.5 at 37°C), with the exception of the 
enzyme which was prepared in 1.0% (w/v) BSA solution. Upon preparation, 
reaction reagents were added to a microplate in specific volumes (Table 3.3), 
where they were mixed and incubated at 37°C for 5 minutes prior to being placed 
and monitored in a plate reader at 340 nm.  
 
Table 3.3 Lactate dehydrogenase assay reagents (volume per well) 
Reagent Blank Positive Control 
0.13 mM β-NADH  186.6 µL 186.6 µL 
34 mM Sodium Pyruvate 6.7 µL 6.7 µL 
1.0 % BSA 6.7 µL - 
0.5 U/mL LDH - 6.7 µL 
 
3.2.4 Aspartate aminotransferase  
 Aspartate aminotransferase (AST), also known as serum glutamic 
oxaloacetic transaminase, facilitates and accelerates the reversible conversion of 
aspartate and α-ketoglutarate to oxaloacetate and glutamate (Figure 3.4). AST is 
not organ specific and can primarily be found in significant amounts in the liver 
and heart, with minimal amounts in the kidneys and brain. Damage experienced 
by these organs result in the elevation of AST levels in serum. Serum levels 
typically correlate with the extent of damage experienced. Measurement of AST 
activity following brain injury via coupled kinetic photometric analysis offers 
insight regarding the role of amino acid metabolism in the TCA cycle. 
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Fig.3.4 Enzymatic reaction of aspartate aminotransferase  
 
 To assay the activity of aspartate aminotransferase, the reagent cocktail 
was prepared as described in Table 3.4. AST enzyme solution (0.25 U/mL) was 
prepared in a 100 Mm KH2PO4 (pH 7.4). The reaction was monitored at 340 nm, 
loading the volumes of reagents and enzyme according to Table 3.5.  
 
Table 3.4 Aspartate aminotransferase assay cocktail mixture 
Reagent Concentration 
L-aspartic acid 134 mM 
α-ketoglutaric acid 6.64 mM 
β-NADH 0.24 mM 
LDH 5 U/mL 
malate dehydrogenase 1.25 U/mL 
KH2PO4 buffer 50 mM 
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Table 3.5 Aspartate aminotransferase assay reagents (volume per well) 
Reagents Blank Positive 
Control 
AST assay cocktail mixture 200 µL 195 µL 
AST enzyme solution - 5 µL 
 
3.2.5 Malate dehydrogenase  
 Malate dehydrogenase (MDH) is an oxidoreductase enzyme that 
participates in the reversible catalysis of the conversion of L-malate to 
oxaloacetate using NAD+ (Fig.3.5). Research indicates increased MDH activity in 
Alzheimer’s disease is consequential of oxidative stress (Shi and Gibson 2011). 
Thus, quantifying the activity of MDH post-TBI provides insight into the 
correlation of oxidative stress and neurodegenerative diseases. Prior to loading 
wells (Fig.3.5), assay reagents and enzymes were prepared in 100 mM KH2PO4 
buffer (pH 7.4). This assay was monitored at 340 nm in a plate reader. 
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+           H
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Fig.3.5 Enzymatic reaction of malate dehydrogenase  
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Table 3.6 Malate dehydrogenase assay reagents (volume per well) 
Reagents Blank Positive Control 
100 mM KH2PO4 180 µL 175 µL 
3.75 mM  β-NADH 13.3 µL 13.3 µL 
6 mM  Oxaloacetate 6.7 µL 6.7 µL 
5 U/mL MDH enzyme 
solution 
- 5 µL 
 
3.2.6 Cytochrome C oxidase 
 Cytochrome C oxidase (Cyt-c) is a mitochondrial enzyme that catalyzes 
the conversion of molecular oxygen to water (Fig.3.6), in Complex IV of the 
respiratory chain, and functions in providing energy to the cell via coupling 
electron transport and oxidative phosphorylation. Cyt-c activity is based upon the 
photometric assessment of the decrease in absorbance of reduced cytochrome c 
at 550 nm, which occurs subsequently after oxidation by Cyt-c (Fig.3.6).  
 
Cytochrome c (reduced) + 2H
+
+ 
1
2
 O2   
Cyt-c
→   Cytochrome c (oxidized) + H2O 
Fig.3.6 Enzymatic reaction of cytochrome C oxidase  
 
All reagents utilized in this assay were prepared in 100 mM KH2PO4 buffer 
(pH 7.4 at 37°C), with the exception of reduced cytochrome c and cytochrome C 
oxidase enzyme. Cytochrome c was prepared in 10 mM KH2PO4 buffer and 
reduced using 5 mg of ascorbic acid. The cytochrome C and ascorbic acid 
solution was then placed in a cellophane membrane, and was dialyzed in 10 mM 
KH2PO4 buffer for 24 hours in efforts to remove excess ascorbic acid from the 
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dialysate (cytochrome C and ascorbic acid solution). The cytochrome C oxidase 
enzyme was prepared in 250 mM sucrose solution with 1% Tween 80 (v/v). 
Reagents and enzyme were added to the microplate as described in Table 3.7, 
with the addition of test samples, which were added in equivalent volumes to the 
enzyme. Reactions in the microplate were equilibrated to 37°C prior to 
spectrophotometric analyses. 
 
Table 3.7 Cytochrome C oxidase assay reagents (volume per well) 
Reagents Blank Positive Control 
10 mM KH2PO4  180 µL 180 µL 
1.0 % (w/v) reduced 
cytochrome c 
13.3 µL 13.3 µL 
100 mM potassium ferricyanide 6.7 µL - 
0.02 mg/mL Cyt-c enzyme 
solution 
- 6.7 µL 
 
3.2.7 ATP synthase  
 ATP synthase is a membrane protein that plays a pivotal role in energy 
metabolism, as it is responsible for catalyzing the phosphorylation of ADP to ATP 
(Fig 3.7). A deficiency or decrease in ATP synthase activity results in impaired 
ATP production. To determine ATP synthase activity, assay reagents were 
prepared in Tris buffer (pH 8.0) and loaded into microplate wells in volumes 
described in Table 3.8. This assay was monitored spectrophotometrically at 340 
nm via the indirect reactions of LDH and PK.  
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Fig.3.7 Enzymatic reaction of ATP synthase assay 
 
Table 3.8 ATP synthase reagents (volume per well) 
Reagent Blank Positive Control Test Sample 
100 mM Tris base 6 µL 5 µL 1 µL 
2 mM MgCl2 5 µL 5 µL 5 µL 
50 mM KCl 5 µL 5 µL 5 µL 
0.2 mM EDTA 5 µL 5 µL 5 µL 
0.23 mM β-NADH 170 µL 170 µL 170 µL 
1 mM PEP 9 µL 9 µL 9 µL 
1.4 U/mL PK/LDH  - 1 µL - 
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3.2.8 Hypoxanthine-guanine phosphoribosyltransferase  
 Purines are nitrogenous-based precursors in DNA/RNA synthesis that can 
be synthesized de novo or recycled by salvage pathways. Purine salvage is said 
to save the energetic cost of de novo synthesis, as it forms purine nucleoside 
monophosphates by attaching purine bases derived from the degradation of 
nucleic acids and nucleotides to 5-phosphoribosyl-1-pyrophosphate (PRPP). 
Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) is a salvage enzyme 
responsible for converting hypoxanthine to inosine monophosphate (IMP) 
(Fig.3.8 reaction 1) and guanine to guanosine monophosphate (GMP) (Fig.3.8 
reaction 2). Deficiency in HGPRT activity clinically manifests as Lesch-Nyhan 
syndrome, a severe neurological disorder characterized by uncontrollable self-
mutilation and the overproduction of uric acid.  
In assaying the activity of HGPRT, reaction reagents were prepared 
according to the PRECICE® HPRT Assay Kit protocol obtained from Novocib 
(http://www.novocib.com/HPRT_Assay_Kit.html). Briefly, reaction mixture 1x 
without PRPP was prepared by dissolving dithiothreitol, nicotinamide adenine 
dinucleotide, bacterial inosine-5’-monophosphate dehydrogenase in 1 mL of 
reaction buffer 10x containing hypoxanthine. Reaction mixture 1x with PRPP was 
prepared similarly, with the addition of 2 mM PRPP. Human recombinant HPRT 
enzyme solution (75 mU/mL) was prepared using deionized water. Loaded 
volume of assay reagents per well are displayed in Table 3.9. This assay was 
monitored at 340 nm. 
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Fig.3.8 Enzymatic reactions of hypoxanthine-guanine 
phosphoribosyltransferase  
 
Table 3.9 Hypoxanthine-guanine phosphoribosyltransferase reagents 
 (volume per well) 
 
Reagent Blank Positive Control 
Reaction 1x without PRPP 200 µL - 
Reaction 1x with 2 mM PRPP - 195 µL 
75 mU/mL HGPRT enzyme - 5 µL 
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CHAPTER 4 
ENZYME ANALYSIS OF SPECIFIC ENERGY RELATED ENZYMES 
NITRATED BY MODERATE TRAUMATIC BRAIN INJURY 
 
4.1 Overview 
  Proper brain functionality is dependent upon a sufficient supply of 
glucose for energy metabolism. Thus, biochemical processes involved in cellular 
respiration are important in producing ATP for the brain. Reduced energy 
metabolism and mitochondrial dysfunction are associated with traumatic brain 
injury, as studies have demonstrated that protein nitration is a consequence of 
TBI through the production of ROS/RNS (Deng et al. 2007, Orihara et al. 2001). 
Antioxidants, such as glutathione, combat the deleterious effects of oxidation 
by scavenging ROS/RNS, inhibiting propagation of lipid peroxyl radicals, and 
removing neurotoxic byproducts such as 4-hydroxynonenal, acrolein, and 
malondialdehyde. GCEE, an ethyl ester moiety of gamma-glutamylcysteine, 
exhibits antioxidant activity by increasing glutathione production. Previous 
studies have demonstrated that the administration of GCEE following TBI has 
protective effects against protein nitration through the elevation of glutathione 
(Reed et al. 2009, Drake et al. 2002, Lok et al. 2011). This study used controlled 
cortical impact on Wistar rats to induce TBI. This choice in experimental TBI 
model permitted the observation of neurological and pathological changes that 
contribute to secondary injury based upon severity of injury induced (Potts et al 
2009, Dixon et al 1991) From brain homogenate, enzymatic activity of energy 
related proteins that have been identified as nitrated in moderate TBI were 
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studied. Results demonstrate an increase in enzymatic activity upon GSH 
elevation via GCEE administration in several key enzymes including 
glyceraldehyde-3-phosphate dehydrogenase, pyruvate kinase, lactate 
dehydrogenase, aspartate aminotransferase, malate dehydrogenase, 
cytochrome C oxidase, and ATP synthase, thereby indicating GCEE is a 
potential therapeutic strategy to restore energy related proteins in the brain post-
TBI via GSH elevation.  
 
4.2 Introduction 
 Traumatic brain injury is a sudden spontaneous event in which brain 
dysfunction occurs as a result of an external force. The dysfunction experienced 
is a result of the external physical impact occurring at the site of injury, and is 
termed primary damage. Primary damage subsequently initiates immediate or 
delayed physiological disturbances, known as secondary damage, which 
collectively result in mitochondrial dysfunction. After TBI, the mitochondria 
experience an affluence of toxic radical species that decrease ATP production.  
 Mitochondrial ATP production typically occurs through a cascade of 
reactions, in which electrons carried by NADH and FADH2 interact with O2 via a 
respiratory proton pump (Pieczenik and Neustadt 2007). In the pathological 
circumstances of traumatic brain injury, ATP production is often limited due to 
nitration of enzymes responsible for facilitating the biochemical reactions of 
cellular respiration. The scavenging of ROS/RNS is protective against oxidative 
stress; however, the antioxidant glutathione exists in the brain at lower 
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concentrations than other organs and is easily depleted post-TBI (Lok et al. 
2011, Dringen 2000). Strategies that increase glutathione concentrations post 
brain injury, such as GCEE, show therapeutic promise in protecting proteins 
against nitration and neurons against oxidative stress.  
  In this study, we assessed the efficacy of GCEE as a therapeutic 
strategy in the overall restoration of brain energy metabolism via glutathione 
elevation following the onset of injury. Energy-related enzymes were assayed at 
various time points to determine the optimum time point for treatment.  
 
4.3 Materials and Methods 
4.3.1 Chemicals and Materials 
 All chemicals utilized were obtained from Sigma-Aldrich (St Louis, MO, 
USA) with the exception of GCEE, purchased from Bachem (Torence, CA, USA), 
β-NADH and Tris Base, which was purchased from Thermo Fisher Scientific 
(Waltham, MA, USA).  
4.3.2 Surgical, Treatment, and Sample Preparation  
 Please refer to Chapter 3, sections 3.1.1, for information regarding 
surgical procedures. Sham animals served as the control, and were not injured or 
treated. Saline and GCEE animals received a moderate CCI and an 
intraperitoneal injection of saline or GCEE (150 mg/kg) according to their 
corresponding experimental groupings, at either 30 or 60 minutes post-injury. All 
rats were sacrificed via decapitation 24 hours post-injury. Upon sacrifice, whole 
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brain was harvested, suspended, sonicated, and homogenized in 10 mM HEPES 
buffer (pH 7.4), containing 137 mM NaCl, 4.6 mM MgSO4, as well as proteinase 
inhibitors leupeptin (0.5 mg/mL), pepstatin (0.7 ug/Ml), type II soybean trypsin 
inhibitor (0.5 µg/mL), and PMSF (40 µg/mL). Brain homogenates were 
centrifuged to remove debris at 14,000 x g for 10 minutes, and supernatant was 
collected.  
4.3.3 Glyceraldehyde-3-phosphate dehydrogenase assay 
 The enzymatic activity of glyceraldehyde-3-phosphate dehydrogenase 
assay (GAPDH) was determined through the glycerate-1,3 biphosphate coupled 
assay at 340 nm. In the assay, the 0.2 mL reaction mixture contained 100 mM 
triethanolamine hydrochloride pH 7.6, 100 mM D(-)3-phosphoglyceric acid 
(cyclohexylammonium) salt, 200 mM L-cysteine hydrochloride monohydrate, 100 
mM MgSO4, 7 mM β-NADH, 34 mM ATP, and 200 units 3-phosphoglyceric 
phosophokinase. The addition of 6.8 µL of GAPDH or brain sample initiated the 
reaction. Upon initiation, the reaction was monitored at room temperature for 15 
minutes in a microplate reader. One unit of GAPDH will reduce one micromole of 
3-phosphoglycerate to D-glyceraldehyde-3-phosphate per minute under the 
conditions previously mentioned. 
4.3.4 Pyruvate kinase assay 
  The spectrophotometric determination of pyruvate kinase (PK) 
enzymatic activity coupled the production of pyruvate to the oxidation of β-NADH 
via PK and lactate dehydrogenase (LDH) reactions, which were equilibrated to 
37o C and monitored at 340 nm for 15 minutes in a microplate reader. The 0.2 
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mL reaction mixture contained 100 mM KH2PO4 (pH 7.6), 8 mM 
phosphoenolpyruvate (PEP), 3 mM β-NADH, 100 mM MgSO4, 40 mM ADP, and 
500 units LDH. The reaction was initiated by the addition of 6.7 µL of enzyme or 
brain sample. One unit of activity is the amount of PK catalyzing the conversion 
of PEP to pyruvate and one unit of LDH reducing 1.0 µmole of pyruvate to L-
lactate per minute.  
4.3.5 Lactate dehydrogenase assay 
  Lactate dehydrogenase (LDH) activity was quantified by the change in 
absorption at 340 nm resulting from the oxidation of β-NADH in a microplate 
reader. The reaction mixture, containing 0.13 mM β-NADH, 34 mM sodium 
pyruvate, and 1.0% (w/v) BSA, was started upon the addition of 6.7 µL of LDH 
enzyme or brain sample and equilibrated to 37°C. One unit of LDH activity will 
reduce 1.0 µmole of pyruvate to l-lactate per minute at pH 7.5 at 37o C. This 
assay was conducted for 15 minutes. 
4.3.6 Aspartate aminotransferase assay 
  The activity of aspartate aminotransferase (AST) was measured 
spectrophotometrically at 340 nm for 15 minutes by MDH coupled 
spectrophotometric assay. The standard reaction mixture contained 134 mM L-
aspartic acid (pH 7.4), 6.64 mM of α-ketoglutaric acid, 240 mM β-NADH, 5 units 
LDH, 1.25 units MDH, and 50 mM Na3PO4. The addition of five microliters of AST 
enzyme or brain sample at room temperature initiated the reaction. This assay 
was carried out using a microplate reader. Under the conditions mentioned 
above, one unit oxidizes one micromole of β-NADH per minute. 
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4.3.7 Malate dehydrogenase assay 
MDH activity was determined spectrophotometrically at room 
temperature using a microplate reader to quantify the decrease in absorbance at 
340 nm for 15 minutes. The reaction mixture contained 100 mM of KH2PO4 pH 
7.4, 6 mM oxaloacetic acid, and 3.75 Mm β-NADH. The addition of five microliters 
of MDH or brain sample to reaction mixture initiated the assay. One unit of 
malate dehydrogenase catalyzes the conversion of one micromole of oxaloacetic 
acid and β-NADH to L-malate and β-NAD+ per minute. 
4.3.8 Cytochrome c oxidase assay  
 The enzymatic activity of cytochrome c oxidase was assayed at 550 nm 
for 15 minutes using a microplate reader. Prior to performing this assay, a stock 
solution containing ten milligrams per milliliter of Cyt-c was reduced with excess 
sodium L-ascorbate, and then dialyzed before use. The reaction mixture 
contained 2 µg of reduced cytochrome C and 10 mM KH2PO4 (pH 7). A complete 
reaction mixture along with the addition of 100 mM K3Fe(CN)6 served as the 
blank. The reaction was started by the addition of 6.7 µL of Cyt-c or brain sample 
and equilibrated at 37oC. One unit of cytochrome c oxidase oxidizes one 
micromole of reduced Cyt-c to oxidized Cyt-c per minute.  
4.3.9 ATP Synthase assay  
 The activity of ATP synthase was determined via PK-LDH coupled 
assay. Standard reaction mixture contained 100 mM Tris pH 8, 2 mM MgCl2, 50 
mM KCl, 0.2 mM EDTA, 0.23 β-NADH, 1 mM PEP. The addition of 1.4 units PK 
and 1.4 units LDH to the reaction mixture served as the enzyme control. This 
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reaction was initiated upon the addition of 1 microliter of PK/LDH enzyme or 
brain sample and was assayed at 30oC using a microplate reader.  
4.3.10 Statistical Analysis 
All data were analyzed using ANOVA (two-way) and statistical significance was 
set at p < 0.05. Tukey’s adjustments were made for ANOVA to determine which 
treatments were significant. 
4.4 Results 
4.4.1 Glyceraldehyde-3-phosphate dehydrogenase activity 
 
Fig.4.1 Activity of glyceraldehyde-3-phosphate dehydrogenase in traumatically 
brain injured GCEE treated animals compared to saline treated and sham animals. 
Bars are representative of mean ± S.E.M., n = 3 for each group. 
 
 The glyceraldehyde-3-phosphate dehydrogenase assay was performed 
to assess the enzyme activity of GAPDH upon traumatic brain injury in rats and 
the efficacy of GCEE in restoring GAPDH enzyme activity. The administration of 
saline and GCEE following TBI shows an increase in the enzyme activity of 
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glyceraldehyde-3-phosphate dehydrogenase compared to sham, but was not 
statistically significant (p > 0.05).  The administration of saline 30 minutes post 
injury had a greater effect on the rats in comparison to those treated with saline 
60 minutes post-TBI; whereas, the administration of GCEE 60 minutes post-TBI 
had a greater effect on the rats in comparison to those treated with GCEE 30 
minutes post-injury. However, the differences in treatment time were marginally 
statistically significant compared to controls (p = 0.0593).  
4.4.2 Pyruvate kinase activity 
 
Fig.4.2 Activity of pyruvate kinase in traumatically brain injured GCEE treated 
animals compared to saline treated and sham animals. Bars are representative of 
mean ± S.E.M., n = 3 for each group, *p = 0.0254, **p = 0.0226. 
 
The catalytic activity of PK using the pyruvate kinase assay was 
determined. A non-significant reduction in activity was observed following the 
administration of saline 30 minutes after injury compared to sham, but increased 
within 60 minutes (Fig.4.2). PK activity significantly increased post injury 
* 
** 
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following the administration of GCEE 30 and 60 minutes post-TBI compared to 
sham and saline treated animals (p = 0.0129), with an elevation in  activity at 60 
minutes.  
4.4.3 Lactate dehydrogenase activity 
 
Fig.4.3 Activity of lactate dehydrogenase in traumatically brain injured GCEE 
treated animals compared to saline treated and sham animals. Bars are 
representative of mean ± S.E.M., n = 3 for each group. 
 
The utilization of the lactate dehydrogenase assay quantified the activity 
of LDH. The administration of saline and GCEE at 30 and 60 minutes post-injury 
increased LDH activity compared to the control. However, this was not a 
significant increase (p > 0.05). Although the administration of both saline and 
GCEE 60 minutes post-injury had a more pronounced effect on rats in 
comparison to those treated at 30 minutes post-injury, the elevation in activity 
was non-significant (p > 0.05). 
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4.4.4 Aspartate aminotransferase activity 
 
Fig.4.4 Activity of aspartate aminotransferase in traumatically brain injured GCEE 
treated animals compared to saline treated and sham animals. Bars are 
representative of mean ± S.E.M., n = 3 for each group, *p = 0.0013. 
 
The activity of aspartate aminotransferase corresponding to the 
administrative effect of treatment was quantified using the AST assay. 
Measurements of aspartate aminotransferase activity in traumatically brain 
injured rats demonstrated a slight reduction following saline administration 30 
minutes after injury compared to sham, but significantly increased within 60 
minutes compared to saline administered 30 minutes following traumatic brain 
injury  (p = 0.0013). The administration of GCEE post-TBI increased activity 
compared to sham and saline treated animals sans significance (p > 0.05); 
however, the administration of GCEE 60 increased activity compared to GCEE 
administered 30 minutes post injury was statistically significant (p = 0.0013). 
Observations of the effect of time of treatment demonstrated significance, where 
* 
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administration of saline and GCEE 60 minutes upon injury increased enzyme 
activity compared to administration at 30 minutes (Fig.4.4). 
4.4.5 Malate dehydrogenase activity 
 
Fig.4.5 Activity of malate dehydrogenase in traumatically brain injured GCEE 
treated animals compared to saline treated and sham animals. Bars are 
representative of mean ± S.E.M., n = 3 for each group, *p = 0.0024, **p = 0.0200,  
***p < 0.001. 
 
  
Using the MDH assay, enzyme activity of MDH was measured post 
incident administration of treatment. Results indicate the administration of vehicle 
(saline) and drug significantly increased activity compared to sham (p = 0.0025). 
A more robust significant increase in activity was observed following the 
administration of saline and GCEE 60 minutes post-TBI, in comparison to 
administration at 30 minutes (p < 0.001). Statistical analyses determined a two-
way interaction between treatment and time for malate dehydrogenase. 
 
* 
** 
*** 
*** 
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4.4.6 Cytochrome C oxidase activity 
 
Fig.4.6 Activity of cytochrome C oxidase in traumatically brain injured GCEE 
treated animals compared to saline treated and sham animals. Bars are 
representative of mean ± S.E.M., n = 3 for each group. 
 
The investigation of the catalytic activity of cytochrome C oxidase was 
performed using the Cyt-c assay. Activity upon administration of saline and 
GCEE in traumatically brain injured rats was determined to be not statistically 
significant (p > 0.05), with the greatest increase in activity observed 60 minutes 
post injury.  
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4.4.7 ATP synthase activity 
 
Fig.4.7 Activity of ATP synthase in traumatically brain injured GCEE treated 
animals compared to saline treated and sham animals. Bars are representative of 
mean ± S.E.M., n = 3 for each group. 
 
In determining the activity of ATP synthase post-TBI, the ATP synthase 
assay was used. Reductions in activity were observed upon the administration of 
saline compared to control (Fig.4.7). Despite the increase in activity observed 
after the administration of GCEE at both time points compared to saline treated 
and sham animals, differences did not achieve statistical significance (p > 0.05).  
 
4.5 Discussion 
The pathogenic role of oxidative stress in neurodegenerative disease in 
relation to glutathione depletion has been well documented. Research 
demonstrates the contribution of oxidative stress to the energy crisis observed 
post-TBI. Studies show the attenuation of oxidative stress experienced upon 
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traumatic brain injury impedes the disruption of redox homeostasis, which can 
improve cellular and functional outcomes after injury. Given the complexity and 
heterogeneity of TBI, therapeutic approaches to combat the deleterious effects 
are still non-existent. However, the administration of chemical substances, such 
as GCEE, in experimental settings have been shown to increase intracellular 
glutathione levels, which in turn alleviates neurotoxic byproducts accumulated 
upon injury, and offers therapeutic promise. Here we investigated the enzymatic 
activity of the energy related proteins glyceraldehyde-3-phosphate 
dehydrogenase, pyruvate kinase, lactate dehydrogenase, aspartate 
aminotransferase, malate dehydrogenase, cytochrome C oxidase, and ATP 
synthase, which were found to be excessively nitrated in moderate TBI, and 
assessed the efficacy of GCEE as a potential therapeutic strategy in improving 
brain energy metabolism following moderate TBI.  
 Glyceraldehyde-3-phosphate dehydrogenase is a multifunctional protein 
with glycolytic, sensory, and apoptotic activities expressed ubiquitously in 
tissues. Studies demonstrate the functional role of glyceraldehyde-3-phosphate 
dehydrogenase in the progression of neurodegenerative disease, as impaired 
glycolytic function and increased pro-apoptotic function is observed in 
Alzheimer’s and Huntington’s disease (AD and HD, respectively) (Butterfield et 
al. 2010, Hara et al. 2006, Nicholls, Li, and Liu 2012). In glycolysis, this cytosolic 
enzyme catalyzes the oxidative phosphorylation of glyceraldehyde-3-phosphate 
to 1, 3-biphosphate glycerate by converting NAD+ to NADH. The catalysis of this 
reaction also produces ATP through substrate level phosphorylation. Impairment 
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of GAPDH glycolytic activity in persons who have experienced TBI may 
contribute to an increased concentration of glyceraldehyde-3-phosphate and 
dihydroxyacetone. The accumulation of both compounds give rise to 
methylgloxal, a highly oxidative metabolite associated with DNA and protein 
modification (Murata-Kamiya and Kamiya 2001). During pathologic conditions of 
oxidative stress, such as those experienced in the brain through TBI, 
glyceraldehyde-3-phosphate dehydrogenase inactivation triggers cell death 
signaling pathways through aggregation, translocation, and binding (Schuppe-
Koistinen et al 1994, Tarze et al 2007). Specifically, the accumulation and 
translocation of cytosolic GAPDH to the nucleus increases levels of DNA 
damage and inhibits DNA repair, which may in turn induce transcription of cell 
death mediated genes (Butterfield et al 2010). The mitochondrial binding of 
GAPDH is associated with apoptosis via membrane depolarization, which 
respectively leads to calcium uptake, matrix swelling, and the release of 
cytochrome C (Butterfield et al 2010). Attenuation of oxidative stress via 
administration of GCEE following traumatic brain injury may improve 
maintenance of glycolytic function while simultaneously reducing neuronal cell 
death commonly observed in TBI. 
In the final step of glycolysis, pyruvate kinase converts 
phosphoenolpyruvate (PEP) to pyruvate, which produces ATP through substrate 
level phosphorylation. Pyruvate kinase exists in four isoforms: M1, M2, R, and L. 
Pyruvate kinase M1 is typically expressed in the brain. Evidence indicates 
reduced enzyme activity of PK in individuals with amnestic mild cognitive 
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impairment (MCI), a predecessor condition frequently experienced upon 
development of Alzheimer’s disease, and posits that protein function is impaired 
by oxidative modification (Reed et al 2008). Given its glycolytic nature, pyruvate 
kinase is vital to the production of energy in the brain, as pyruvate produced by 
its catalytic activity acts as an intermediate to continue cellular respiration. 
Oxidative modifications of pyruvate kinase observed in individuals with MCI have 
been suggested to result in limited ATP production and altered ATP-dependent 
cellular activities, such as signal transduction and cell membrane potential 
maintenance (Reed et al 2008). Similar manifestations may be observed in 
persons with TBI, as pyruvate kinase is also found to be oxidatively modified. 
The significantly increased enzyme activity of PK upon the administration of 
GCEE 30 and 60 minutes compared to sham and saline treated animals 
following traumatic brain injury suggests potential improvements of redox 
homeostasis and ATP production outcomes following TBI. 
Lactate dehydrogenase, a cytoplasmic enzyme, exists in five isoforms. 
Although the isoforms have similar catalytic functions, their tissue distribution 
varies. LDH-1 is expressed within the brain. Damage to tissues results in 
increased serum levels of LDH, respective of isozyme expression in tissue type. 
Thus, the utilization of serum LDH levels as a biomarker are of clinical interest, 
as it reflects pathological conditions of specific tissues. Under glycolytic 
conditions, the reduction of pyruvate to lactate is catalyzed by lactate 
dehydrogenase using NADH. The utilization of lactate as a substrate for 
gluconeogenesis ensures the perpetuation of glucose and energy metabolism, in 
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circumstances of limited glucose availability.  Lowered glucose metabolism 
attributed to LDH dysfunction has been observed in AD, Parkinson’s disease 
(PD), and MCI (Reed et al 2008, Hoyer 2004).  Impairment in the catalytic activity 
of lactate dehydrogenase via oxidative modifications could result in reduced 
gluconeogenesis and the overproduction and/or accumulation of pyruvate (Reed 
et al 2008). Inhibition of protein oxidative damage associated with TBI via 
administration of GCEE may increase LDH enzymatic activity, which may 
successively result in increased brain lactate levels, glucose production, NAD+ 
production, and energy metabolism.  
Aspartate aminotransferase is a transaminase that exists as two forms, 
cytosolic and mitochondrial. Its expression can be observed in multiple tissues, 
including the brain, liver, heart, skeletal muscle, kidneys, and red blood cells. 
Similar to LDH, serum levels of AST are used as a biomarker to assess extent of 
injury in pathological conditions. Aspartate aminotransferase catalytic function is 
vital to amino acid metabolism, as it is responsible for the interconversion of 
oxaloacetate and glutamate to aspartate and α-ketoglutarate. α-ketoglutarate 
generated from the anaplerotic transamination of glutamate serves as a key 
intermediate in the TCA cycle via cyclization continuation and production of 
NADH. Impairments in AST activity may contribute to the increased 
concentration of glutamate observed following primary TBI. Here we report 
increased enzymatic activity following the administration of GCEE 60 minutes 
post-TBI compared to saline treated and sham. The ability of GCEE to impede 
the cascade of ROS production resulting from glutamate-induced excitotoxicity 
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and increased calcium influx may alleviate AST inactivation due to protein 
oxidation. 
Malate dehydrogenase is an oxidoreductase that exists within the cell as 
either a mitochondrial or cytoplasmic isozyme. Mitochondrial MDH participates in 
the oxidation of malate to oxaloacetate using NAD+, in the final step of the TCA 
cycle before regeneration, while cytoplasmic MDH participates in the malate-
aspartate shuttle which permits the passage of malate through the mitochondria 
membrane for conversion into oxaloacetate via exchange of reducing 
equivalents. Malate dehydrogenase has been shown to be oxidatively modified in 
persons with MCI (Reed et al 2008), and its activity has been demonstrated to be 
elevated in persons dying of AD (Shi and Gibson 2011, Bubber et al 2005, Oop 
den Velde and Stam 1976). Impairments in the activity of MDH may result in 
reduced oxaloacetate and ATP production in persons with TBI. Increases in MDH 
activity may elevate oxaloacetate levels, which may in turn decrease the 
increasingly high levels of glutamate (and excitotoxicity) experienced after brain 
injury, as oxaloacetate has been demonstrated to scavenge glutamate (Zlotnik et 
al 2010). Increases in MDH activity may also increase oxaloacetate levels and 
passage of reducing equivalents to ETC, which may profoundly increase the 
reduced ATP production exhibited in TBI affected individuals. In this current 
study, we have demonstrated that the administration of GCEE significantly 
increases MDH activity in TBI rats, where treatment administered 60 minutes 
post injury significantly increases activity compared to treatment administered at 
30 minutes. The ability of GCEE to increase activity suggest its efficacy as a 
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therapy to attenuate oxidative stress and increased MDH susceptibility to 
oxidative modification.  
Cytochrome C oxidase, also known as Complex IV of the electron 
transport chain, catalyzes the transfer of electrons from ferrocytochrome c to 
molecular oxygen, and the conversion of molecular oxygen to water. In mammals 
this enzyme consists of 13 subunits responsible for regulatory, assembly, and 
catalytic functions. Three of the subunits have catalytic function, while the other 
10 subunits have regulation and assembly function. The activity of Cyt-C is said 
to be an indicator of the oxidative capacity of cells under normal physiological 
conditions (Srinivasan and Avadhani 2012). Under normal physiological 
conditions, the mitochondria produce ROS in small amounts. As a result of brain 
injury, the opening of the mitochondrial permeability transition pore initiates the 
overproduction of ROS and apoptosis via cytochrome C release. Observations of 
deficient cyt-C activity via protein dysfunction has been correlated with clinical 
and experimental manifestations of mitochondrial dysfunction resulting in Leigh 
syndrome, stroke, AD, PD, and TBI (Nelson and Silverstein 1994, Hovda et al 
1991). Reduced alterations in cytochrome C oxidase activity may directly affect 
cellular ATP levels and calcium homeostasis. The attenuation of oxidative stress 
via administration of GCEE may indirectly increase ATP levels in individuals 
suffering from traumatic brain injury by improving mitochondrial function, 
decreasing calcium influx, and decreasing susceptibility of Cyt-C to oxidative 
modifications. 
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ATP synthase, also known as Complex V of the electron transport chain, 
plays a key role in energy production and transduction in cells. ATP synthase is 
an enzyme whose catalytic mechanism involves the utilization of energy from the 
proton gradient established by the ETC to synthesize ATP via phosphorylation of 
ADP. Reduced energy metabolism as well as mitochondrial dysfunction has been 
subsequently observed in TBI, as well as other neurodegenerative disease, as a 
consequence of oxidative stress and damage. Here we report reduced activity of 
ATP synthase upon brain injury compared to the control, which is not statistically 
significant. Reductions in ATP synthase activity are indicative of oxidative 
modifications incurred by protein via increased ROS/RNS production after TBI, 
possibly resulting in depressions in ETC and impaired ATP production. The 
administration of GCEE following injury resulted in non-significant increases in 
ATP synthase activity. This suggests that the GCEE is protective in reducing the 
oxidative modifications of ATP synthase experienced post traumatic brain injury. 
In this study, we assessed the enzymatic activity of energy related 
proteins identified as being excessively nitrated. Oxidative modification of 
proteins contribute to the alterations of enzyme activities found in many 
neurodegenerative disorders. Slight reductions in the activities of some energy 
related proteins were observed upon the administration of the vehicle following 
TBI, where pyruvate kinase and aspartate aminotransferase activity were 
reduced upon administration at 30 minutes, while ATP synthase activity was 
reduced at 30 and 60 minutes. Elevations in activities of glyceraldehyde-3-
phosphate dehydrogenase, pyruvate kinase, lactate dehydrogenase, aspartate 
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aminotransferase, malate dehydrogenase, and cytochrome C oxidase upon 
administration of saline are suggestive of saline providing protection from protein 
oxidation incurred post injury. The administration of saline solutions containing 
hydrogen, pyruvate, and lactate have been shown to diminish the effects of 
secondary brain injury by attenuating increased ROS/RNS production, enhancing 
bioenergetics, and improving neurological recovery, respectively (Ichai et al 
2009). All proteins in this current investigation have been found to be 
upregulated, with significant elevations observed in the activities of pyruvate 
kinase and malate dehydrogenase. Given that the administration of GCEE 
attenuates the overproduction of oxidative stress observed after TBI, elevations 
in the activities of proteins upon administration of drug in vehicle compared to 
only vehicle suggests saline’s ability to enhance attenuation of oxidative stress. 
Trends in activities indicated that administration of GCEE 60 minutes post-TBI 
demonstrated the highest level of activity compared to treatment at 30 minutes, 
with significant observations of increased activities in pyruvate kinase, aspartate 
aminotransferase, and malate dehydrogenase. Taken together, these results 
suggests that GCEE is a promising potential therapeutic that increases enzyme 
activity of several key energy related proteins upon administration at one hour 
following traumatic brain injury. 
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CHAPTER 5 
SALVAGE ENZYME ANALYSIS MODIFIED BY PROTEIN NITRATION VIA 
MODERATE TRUAMATIC BRAIN INJURY 
 
5.1 Overview 
 Protein dysfunction via protein modification has been observed in 
all common forms of TBI, and is a result of cellular redox homeostatic 
perturbations. Oxidative modifications in neurodegenerative diseases have been 
demonstrated to decrease the enzymatic activity of an enzyme, in comparison to 
the controls, as studies have reported an inverse correlation between oxidative 
modifications and enzyme functionality, where functional activity decreases as 
oxidative modifications increase (Reed et al. 2008, Aksenov et al. 2000, 
Butterfield et al. 2006, Poon et al. 2005, Reed et al. 2009). Our data suggests 
that cerebral oxidative stress experienced after traumatic brain injury ultimately 
leads to reduced purine recycling, as salvage related enzyme hypoxanthine-
guanine phosphoribosyltransferase (HGPRT) has been demonstrated to be 
oxidatively modified. The administration of GCEE post-TBI upregulates cellular 
glutathione levels (Reed et al 2009, Drake et al 2002, Lok et al 2011), which in 
turn normalizes redox homeostasis via attenuation of ROS/RNS. In an 
exploratory effort to assess the efficacy of GCEE as a potential therapeutic 
strategy for TBI for the restoration of salvage related enzyme HGPRT, 
traumatically brain injured Wistar rats were administered saline or GCEE, with 
the exception of sham animals, 30 minutes post injury. The enzymatic activity of 
hypoxanthine-guanine phosphoribosyltransferase was then determined 
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spectrophotometrically using brain homogenate. A non-significant increase in the 
activity of HGPRT was observed in animals treated with GCEE compared to 
saline treated animals (p > 0.05). Results suggest the correlation of elevated 
antioxidant capacity with increased enzyme activity. Thus, the elevation of 
glutathione via GCEE administration post injury indicates the therapeutic promise 
of GCEE as a potential strategy in the restoration of hypoxanthine-guanine 
phosphoribosyltransferase following traumatic brain injury.  
 
5.2 Introduction 
Purine nucleotides are active participants in a wide variety of biochemical 
processes, such as cell signaling. The strict regulation of their biosynthesis and 
metabolism are therefore important. Purine nucleotides may be assembled from 
“scratch” via de novo synthesis, or “recycled” from preformed bases via salvage 
pathway. The brain depends on the latter mechanism in preserving purine pools, 
as it has a limited capacity for de novo synthesis.  
Our findings are the first to report purine salvage enzyme hypoxanthine-
guanine phosphoribosyltransferase as being oxidatively modified upon TBI. 
Oxidative stress, a hallmark of TBI, is characterized by an imbalance between 
prooxidants and antioxidants. Failure to attenuate oxidative stress is the result of 
the body’s inability to counteract the enhanced formation of toxic radical species. 
Depletion of glutathione levels upon brain trauma increases cellular components 
susceptibility to oxidative modifications, such as structural and functional 
alterations, which ultimately contributes to cellular dysfunction and death. GCEE, 
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a potential therapeutic strategy for TBI, exhibits antioxidant activity by increasing 
glutathione production. Elevations in intracellular glutathione levels restore redox 
homeostasis, which improves cell functional outcomes post-TBI. In this present 
study, we assessed the enzymatic activity of HGPRT after experimental TBI and 
the administration of treatment by conducting a spectrophotometric assay.     
 
5.3 Materials and Methods 
5.3.1 Chemicals and Materials 
 All chemicals utilized were obtained from Novocib (Lyon, France) with 
the exception of GCEE, purchased from Bachem (Torence, CA, USA), PRPP, 
which was purchased from Thermo Fisher Sigma Aldrich (St. Louis, MO, USA).  
5.3.2 Surgical, Treatment, and Sample Preparation  
 Please refer to Chapter 3, sections 3.1.1, for information regarding 
surgical procedures. For information regarding to treatment and sample 
preparation, please refer to Chapter 4, section 4.3.2. 
5.3.3 Hypoxanthine-guanine phosphoribosyltransferase assay 
 Please refer to Chapter 3, section 3.1.3.8, for more information regarding 
the quantification of HGPRT activity using the PRECICE ® HPRT Assay 
(http://www.novocib.com/HPRT_Assay_Kit).  
5.3.4 Statistical Analysis 
 Data was analyzed using ANOVA. Statistical significance was set at p < 
0.05. 
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5.4 Results 
The catalytic activity of HGPRT was determined using the hypoxanthine-
guanine phosphoribosyltransferase assay. A non-significant reduction in activity 
was observed upon the treatment of saline 30 minutes post brain injury 
compared to sham animals (Fig.5.1). The administration of GCEE non-
significantly increased activity compared to saline (p = 0.0963); however, it did 
not restore activity to levels seen in the control, as a slight non-significant 
reduction in activity was observed (p < 0.05). 
 
 
Fig.5.1 Activity of hypoxanthine-guanine phosphoribosyltransferase in 
traumatically brain injured GCEE treated animals compared to saline treated and 
sham animals. Bars are representative of mean ± S.E.M., n = 3 for each group. 
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5.5 Discussion 
Traumatic brain injury is associated with oxidative stress through the 
increased production of reactive oxidants. Oxidative modifications contribute to 
protein nitration and dysfunction exhibited in all common forms of TBI. The 
administration of GCEE following brain trauma elevates glutathione levels and 
decreases oxidative damage.  
In this study, we investigated whether the administration of GCEE in traumatically 
brain injured rats could be utilized as a potential therapeutic strategy in the 
restoration of HGPRT via glutathione elevation following the onset of injury. 
Hypoxanthine-guanine phosphoribosyltransferase is a cytosolic salvage 
enzyme that is expressed in all tissues, and is very abundant in the brain. 
Individuals suffering from Lesch-Nyhan syndrome have deficient hypoxanthine-
guanine phosphoribosyl activity, which results in severe neurological disorders 
characterized by the overproduction of uric acid and self-injurious behavior. 
Specifically, HGPRT catalyzes the conversion of preformed purine bases, 
hypoxanthine and guanine, to inosine monophosphate and guanosine 
monophosphate, respectively. Here we report reduced activity of HGPRT upon 
traumatic brain injury in animals receiving saline compared to control, which is 
not statistically significant.  The role of reductions in hypoxanthine-guanine 
phosphoribosyltransferase activity may cause a deficit in intracellular GTP and 
GTP depletion, despite its indirect participation in the metabolism of guanosine. 
Thus, brains of individuals who have brain trauma may experience impaired G-
protein-mediated signal transduction. During signal transduction, a stimulus is 
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converted into a cellular response. This conversion is stimulated by the 
attachment of a signaling molecule to cell membrane protein receptor, which 
elicits changes in cell function via transmission of signal into cell via second 
messenger. Glucagon and epinephrine are hormones that distinctly control 
glycogen metabolism via response mechanisms. Epinephrine release assists in 
the body’s response to a stressor, while glucagon release is to maintain 
homeostasis by elevating blood sugar. Glycogen may act as an endogenous 
source of metabolic energy, in circumstances when energy metabolism is 
reduced, such as TBI. In this work, we demonstrated that the administration of 
GCEE 30 minutes following brain trauma non-significantly increased HGPRT 
activity to levels almost of normality, referring to activity levels exhibited in control 
animals.  Our data suggests GCEE may indirectly improve or increase the 
metabolism of glycogen upon TBI via attenuation of oxidative damage 
experienced by HGPRT upon injury.   
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Conclusions 
  Oxidative stress, a hallmark of traumatic brain injury, can cause 
perturbations in protein structural and functional activity via oxidative damage. 
The body’s innate ability to combat oxidative stress upon TBI is ineffective, as 
glutathione is depleted. Research demonstrates the ability of gamma-
glutamylcysteine to elevate cellular levels of glutathione in the brain (Drake et al 
2002).  The studies presented in this thesis have investigated the antioxidant 
capabilities of GCEE to increase enzymatic activity of proteins identified as 
excessively nitrated following TBI.  
 The utilization of enzyme assays determined the enzymatic activity of 
several proteins identified as being excessively nitrated following moderate 
traumatic brain injury using GCEE treatment 30 and 60 minutes post injury. 
These enzymes include glyceraldehyde-3-phosphate dehydrogenase, pyruvate 
kinase, lactate dehydrogenase, aspartate aminotransferase, malate 
dehydrogenase, cytochrome C oxidase, ATP synthase, and hypoxanthine-
guanine phosphoribosyltransferase. The goal of the first study was to test our 
hypothesis that GCEE could increase the activity of oxidatively modified energy-
related proteins. Glyceraldehyde-3-phosphate dehydrogenase is responsible for 
the conversion of glyceraldehyde-3-phosphate to 1, 3-biphosphate glycerate in 
the sixth step of glycolysis (see Fig.3.1) and the production of ATP via substrate 
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level phosphorylation. Inactive and impaired GAPDH activity may contribute to 
increased oxidative susceptibility of DNA and protein damage via methylgloxal 
production and nuclear translocation. The administration of GCEE post injury 
increased the enzymatic activity of glyceraldehyde-3-phosphate dehydrogenase 
(Fig.4.1, page 43). Administration 60 minutes post injury had a greater effect on 
the rats in comparison to those treated with saline 30 minutes following trauma 
(Fig.4.1). In the final step of glycolysis, pyruvate kinase assists in the catalysis of 
phosphoenolpyruvate (Fig.3.2, page 27), and in the production of ATP through 
substrate level phosphorylation. Our findings demonstrate a slight reduction in 
PK activity following the administration of saline 30 minutes after TBI compared 
to sham; however, activity increased within 60 minutes (Fig.4.2) Reductions in 
the activity of PK may result in limited ATP and altered signal transduction and 
cell membrane potential maintenance (Reed et al 2008). We also observed a 
significant elevation of PK catalytic activity post injury following the administration 
of GCEE compared to sham and saline treated animals, where a more 
pronounced increase in activity was observed at 60 minutes (Fig.4.2).  
Lactate dehydrogenase catalyzes the reduction of pyruvate to lactate 
using NADH (Fig.3.3, page 28). Deficient LDH activity could result in reduced 
glucose production and the accumulation of pyruvate (Reed et al. 2008). Upon 
the administration of the drug, LDH activity increased compared to control and 
vehicle animals, where the administration of GCEE 60 minutes post injury had a 
greater elevation in activity compared to 30 minutes (Fig.4.3, page 45). Aspartate 
aminotransferase converts oxaloacetate and glutamate to aspartate and α-
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ketoglutarate (Fig.3.4, page 46). Reduced AST activity may contribute to 
increased concentration of glutamate.  Our data demonstrates a slight reduction 
of activity following the administration of saline 30 minutes after injury compared 
to sham, but activity significantly increased within 60 minutes (Fig.4.4, page 62). 
We report elevated activity following the administration of GCEE post-TBI 
compared to saline treated and sham animals, where activity significantly 
increased within 60 minutes (Fig.4.4). Malate dehydrogenase catalyzes the 
oxidation of malate to oxaloacetate (Fig.3.5, page 31). Impaired MDH activity 
may result in reduced oxaloacetate and ATP production. Administration of GCEE 
post-TBI significantly increases MDH activity compared to the control, where 
drug administered 60 minutes after trauma significantly increases activity 
compared to administration at 30 minutes (Fig.4.5, page 47).  
Cytochrome C oxidase catalysis transfers the electrons from 
ferrocytochrome c to molecular oxygen, while converting molecular oxygen to 
water (Fig.3.6, page 32). Reductions in Cyt-C activity may directly affect ATP 
levels and calcium homeostasis. The administration of GCEE upon TBI slightly 
increased the enzyme activity of Cyt-C compared to sham animals, where a 
greater increase in activity was observed at 60 minutes administration compared 
to administration of drug at 30 minutes (Fig.4.6, page 48). ATP synthase 
catalyzes the phosphorylation of ADP. Here, we report a reduction in activity of 
ATP synthase upon injury compared to control (Fig.4.7, page 34). The 
administration of GCEE following trauma increased activity compared to control 
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and vehicle groups, where administration of drug 60 minutes had a greater 
increase in activity than that of 30 minutes (Fig.4.7).  
Hypoxanthine-guanine phosphoribosyltransferase catalysis converts 
hypoxanthine to inosine monophosphate and guanine to guanosine 
monophosphate (Fig.3.8, page 36). A reduction in HGPRT activity was observed 
following TBI (Fig.5.1, page 61). Impaired activity may cause a deficit in GTP and 
GTP depletion. Activity increased upon treatment with GCEE compared to sham 
and saline treated animals (Fig.5.1). 
  Reductions in enzyme activity upon traumatic brain injury suggest 
enzyme susceptibility to oxidative damage induced by oxidative stress. Protein 
oxidative modifications in our study bolsters suggestions of the functional role of 
oxidative stress in the progression of neurodegenerative diseases. The loss of 
enzyme activity attributed to protein oxidative modifications potentially 
contributes to abnormal energy and nucleotide metabolism. The administration of 
GCEE demonstrates elevations in enzymatic activity of energy and salvage 
related proteins in the brain post-TBI, with more pronounced effects observed 
with administration at 60 minutes. This suggests that GCEE may prevent brain 
damage against toxic radical species that cause oxidative stress and protein 
nitration in traumatic brain injury.  
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6.2  Future Studies 
1. (Re-analysis) In our experiments, there are three experimental groups: 
sham, saline, and GCEE. All groups receive a craniotomy; however, saline 
and GCEE groups were further subjected to a moderate TBI via cortical 
contusion. To assess the efficacy of GCEE as a potential therapeutic 
strategy in restoring enzymatic activity of proteins identified as nitrated 
post-TBI, we compared the measurements of activity of enzymes in our 
treatment group, GCEE, to the activities of our control and vehicle groups, 
sham and saline respectively. In most cases, the administration of saline 
30 and 60 minutes post injury exhibited an increase in enzyme activities 
compared to sham animals. Given that research indicates that hydrogen-
rich saline is protective against oxidative damage observed in traumatic 
brain injury (Hou et al 2012), the addition of a TBI only experimental group 
should be included to confirm whether the enzymatic activities of the 
saline group are truly representative of enzyme activities experienced 
post-TBI.  
2. (Re-analysis) An exploratory effort to investigate the effect of 
administration of drug on activity, in a time dependent manner, should be 
performed. Our findings indicate the administration of GCEE 60 minutes 
post-TBI demonstrate a more pronounced elevation in activity of enzymes 
excessively nitrated upon TBI. Here, we only assessed the enzymatic 
activity of hypoxanthine-guanine phosphoribosyltransferase upon 
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treatment with saline and GCEE 30 minutes following traumatic brain 
injury.  
3. Although results from both studies in this work are encouraging, indication 
of their therapeutic promise should be further examined. Both studies 
demonstrated increasing activity of proteins nitrated post-TBI within 
experimental animals 30 and/or 60 minutes after injury; however, 
realistically speaking, an individual may not have access to treatment 30 
or 60 minutes following injury. The delay of treatment upon injury should 
be considered, as an individual suffering a mild to moderate TBI may not 
exhibit prolonged secondary effects of injury. Thus, they may not feel 
inclined to seek treatment. The proposal of potential studies investigating 
the effect of GCEE should include administration of treatment at more 
realistic time points such as 90 minutes, 120 minutes, and so forth.  
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Table 6.1 Supporting data for assessment of glyceraldehyde-3-phosphate 
dehydrogenase activity in experimental TBI groups 
 
 
Groups 
(n = 3) 
 
Δ Abs 
 
 
Mean 
 
Std. 
Deviation 
 
Std. Error 
of Mean 
 
% of 
control 
 
 
Sham 30 
-0.201222  
-0.1499 
 
 
0.052655 
 
0.0304 
 
100 -0.096 
-0.152333 
 
Saline 30 
-0.241333  
-0.1758 
 
 
0.073069 
 
0.042187 
 
117.3 -0.189 
-0.097 
 
GCEE 30 
-0.132556  
-0.1646 
 
 
0.029626 
 
0.017105 
 
109.84 -0.170222 
-0.191 
 
Sham 60 
-0.2105  
-0.1879 
 
 
0.059939 
 
0.034606 
 
100 -0.12 
-0.233333 
 
Saline 60 
-0.151167  
-0.2052 
 
 
0.053671 
 
0.030987 
 
109.19 -0.206 
-0.2585 
 
GCEE 60 
-0.27  
-0.2406 
 
 
0.026879 
 
0.015519 
 
127.99 -0.217333 
-0.234333 
 
ANOVA P value 
Treatment 0.5063 
Time 0.0593 
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Table 6.2 Supporting data for assessment of pyruvate kinase activity in 
experimental TBI groups 
 
 
Groups 
(n = 3) 
 
Δ Abs. 
 
Mean 
 
Std. 
Deviation 
 
Std. Error of 
Mean 
 
% of 
control 
 
 
Sham 30 
-0.082889  
-0.077 
 
 
0.0152 
 
0.0088 
 
100 -0.059778 
-0.088333 
 
Saline 30 
-0.065667  
-0.072 
 
 
0.006568803 
 
0.037925 
 
93.482 
 
-0.0715 
-0.078778 
 
GCEE 30 
-0.151  
-0.1205 
 
 
0.0467 
 
0.027 
 
156.45 
 
-0.066667 
-0.143722 
 
Sham 60 
-0.041556  
-0.0541 
 
 
0.013 
 
0.0075 
 
100 -0.067444 
-0.053444 
 
Saline 60 
-0.053167  
-0.0611 
 
 
0.007757314 
 
0.004478688 
 
112.86 
 
-0.0615 
-0.068667 
 
GCEE 60 
-0.1695  
-0.1096 
 
 
0.053 
 
0.0306 
 
202.33 
 
-0.069 
-0.090167 
 
ANOVA P value 
Treatment 0.0129 
Time 0.2818 
 
Adjustment for Multiple Comparisons: Tukey 
Group Least Square Mean 
Sham -0.06557407 
Saline -0.06654630 
GCEE -0.11500926 
 
Least Squares Means for Treatment  
 Sham Saline GCEE 
Sham - 0.9980 0.0226 
Saline 0.9980 - 0.0254 
GCEE 0.0226 0.0254 - 
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Table 6.3 Supporting data for assessment of lactate dehydrogenase activity in 
experimental TBI groups 
 
 
Groups 
(n = 3) 
 
Δ Abs. 
 
 
Mean 
 
Std. 
Deviation 
 
Std. Error of 
Mean 
 
% of 
control 
 
 
Sham 30 
-0.17844  
-0.041 
 
 
0.2989 
 
0.1725 
 
100 -0.24711 
0.301444 
 
Saline 30 
-0.14522  
-0.139 
 
 
0.0068 
 
0.0039 
 
335.36 
 
-0.13933 
-0.13167 
 
GCEE 30 
-0.13689  
-0.156 
 
 
0.0199 
 
0.0115 
 
376.9 -0.17667 
-0.15422 
 
Sham 60 
-0.18489  
-0.019 
 
 
0.3232 
 
0.1866 
 
100 -0.22489 
0.353778 
 
Saline 60 
-0.12383  
-0.134 
 
 
0.014 
 
0.0081 
 
719.94 
 
-0.12906 
-0.15028 
 
GCEE 60 
-0.18067  
-0.181 
 
 
0.007 
 
0.004 
 
967.76 
 
-0.18761 
-0.17367 
 
ANOVA P value 
Treatment 0.3513 
Time 0.9923 
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Table 6.4 Supporting data for assessment of aspartate aminotransferase activity 
in experimental TBI groups 
 
 
Groups 
(n = 3) 
 
Δ Abs. 
 
Mean 
 
Std. 
Deviation 
 
Std. Error of 
Mean 
 
% of 
control 
 
 
Sham 30 
-0.44078  
-0.36663 
 
 
0.083332 
 
0.048112 
 
100 -0.27644 
-0.38267 
 
Saline 30 
-0.45556  
-0.36478 
 
 
0.082149 
 
0.047429 
 
99.495 
 
-0.34322 
-0.29556 
 
GCEE 30 
-0.411  
-0.42552 
 
 
0.058479 
 
0.033763 
 
116.06 
 
-0.37567 
-0.48989 
 
Sham 60 
-0.29711  
-0.21541 
 
 
0.105065 
 
0.06066 
 
100 -0.09689 
-0.25222 
 
Saline 60 
-0.18567  
-0.22581 
 
 
0.057308 
 
0.033087 
 
104.83 
 
-0.20033 
-0.29144 
 
GCEE 60 
-0.37156  
-0.31996 
 
 
0.046675 
 
0.026948 
 
148.54 
 
-0.28067 
-0.30767 
 
ANOVA P value 
Treatment 0.1113 
Time 0.0013 
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Table 6.5 Supporting data for assessment of malate dehydrogenase activity in 
experimental TBI groups 
 
 
Groups 
(n = 3) 
 
Δ Abs. 
 
Mean 
 
Std. 
Deviation 
 
Std. Error of 
Mean 
 
% of 
control 
 
 
Sham 30 
-0.00996  
-0.0163 
 
 
0.0129 
 
0.0074 
 
100 -0.00788 
-0.03112 
 
Saline 30 
-0.01325  
-0.018889 
 
 
0.0092663 
 
0.0005499 
 
115.74 
 
-0.02958 
-0.01383 
 
GCEE 30 
-0.01498  
-0.022813 
 
 
0.0069807 
 
0.0040303 
 
139.79 
 
-0.02508 
-0.02838 
 
Sham 60 
-0.03092  
-0.0647 
 
 
0.0429 
 
0.0248 
 
100 -0.05017 
-0.113 
 
Saline 60 
-0.18342  
-0.1981 
 
 
0.0128 
 
0.0074 
 
306.18 
 
-0.20375 
-0.20708 
 
GCEE 60 
-0.16467  
-0.2455 
 
 
0.0768 
 
0.0444 
 
379.48 
 
-0.25425 
-0.31758 
 
ANOVA P value 
Treatment 0.0025 
Time < 0.0001 
Treatment*Time 0.0041 
 
Adjustment for Multiple Comparisons: Tukey 
Group Least Square Mean 
Sham -0.04050694 
Saline -0.10848611 
GCEE -0.131415625 
 
Least Squares Means for Treatment  
 Sham Saline GCEE 
Sham - 0.0200 0.0024 
Saline 0.0200 - 0.4744 
GCEE 0.004 0.4744 - 
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Table 6.6 Supporting data for assessment of cytochrome C oxidase activity in 
experimental TBI groups 
 
 
Groups 
(n = 3) 
 
Δ Abs. 
 
Mean 
 
Std. 
Deviation 
 
Std. Error of 
Mean 
 
% of 
control 
 
 
Sham 30 
-0.046  
-0.041685 
 
 
0.005913558 
 
0.003414194 
 
100 -0.03494 
-0.04411 
 
Saline 30 
-0.04239  
-0.042814 
 
 
0.00642726 
 
0.00371078 
 
102.71 
 
-0.03661 
-0.04944 
 
GCEE 30 
-0.03794  
-0.043814 
 
 
0.008186547 
 
0.004726505 
 
105.11 
 
-0.05317 
-0.04033 
 
Sham 60 
-0.05583  
-0.04333 
 
 
0.026 
 
0.015011 
 
100 -0.06072 
-0.01344 
 
Saline 60 
-0.06722  
-0.05317 
 
 
0.013346 
 
0.007705 
 
122.69 
 
-0.05161 
-0.04067 
 
GCEE 60 
-0.04822  
-0.05226 
 
 
0.014862 
 
0.00858 
 
120.6 
 
-0.06872 
-0.03983 
 
ANOVA P value 
Treatment 0.7178 
Time 0.2976 
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Table 6.7 Supporting data for assessment of ATP synthase activity in 
experimental TBI groups 
 
 
Groups 
(n = 3) 
 
Δ Abs. 
 
Mean 
 
Std. 
Deviation 
 
Std. Error of 
Mean 
 
% of 
control 
 
 
Sham 30 
-0.18433  
-0.13504 
 
 
0.049899 
 
0.028809 
 
100 -0.08456 
-0.13622 
 
Saline 30 
-0.15367  
-0.012737 
 
 
0.029166 
 
0.016839 
 
94.323 
 
-0.13244 
-0.096 
 
GCEE 30 
-0.15978  
-0.17411 
 
 
0.037293 
 
0.021531 
 
128.94 
 
-0.14611 
-0.21644 
 
Sham 60 
-0.233  
-0.13678 
 
 
0.102007 
 
0.058894 
 
100 -0.1475 
-0.02983 
 
Saline 60 
-0.08667  
-0.12161 
 
 
0.049826 
 
0.028767 
 
88.911 
 
-0.0995 
-0.17867 
 
GCEE 60 
-0.17067  
-0.19083 
 
 
0.023969 
 
0.01839 
 
139.52 
 
-0.1845 
-0.21733 
 
ANOVA P value 
Treatment 0.1528 
Time 0.8634 
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Table 6.8 Supporting data for assessment of hypoxanthine-guanine 
phosphoribosyltransferase activity in experimental TBI groups 
 
 
Groups 
(n = 3) 
 
Δ Abs. 
 
Mean 
 
Std. 
Deviation 
 
Std. Error of 
Mean 
 
% of 
control 
 
 
Sham 30 
-0.15983  
-0.20667 
 
 
0.041754 
 
0.024106 
 
100 -0.24 
-0.22017 
 
Saline 30 
-0.156  
-0.12044 
 
 
0.032698 
 
0.018878 
 
58.28 
 
-0.11367 
-0.09167 
 
GCEE 30 
-0.16183  
-0.20161 
 
 
0.041985 
 
0.02424 
 
97.554 
 
-0.1975 
-0.2455 
 
ANOVA P value 
Treatment 0.0614 
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